The Infectious Diseases Society of America (IDSA) is an organization of physicians, scientists, and other health care professionals dedicated to the promotion and recognition of excellence in research, patient care, public health, disease prevention, and education in the field of infectious diseases. The Society pursues and represents the concerns of its membership by its organizational structure, journals, meetings, and additional activities.

IDSA's 37th annual meeting will be held November 18-21, 1999 at the Pennsylvania Convention Center in Philadelphia. This meeting features invited scientific presentations of twenty symposia, four plenary sessions, twenty meet-the-professor sessions (over a period of three days), three interactive case-based sessions, original slide and poster presentations of new data, and late breakers which consist of important preliminary research findings.

Funding for this conference coverage at The Body is provided, in part, through an unrestricted educational grant by Bristol-Myers Squibb Immunology and Glaxo Wellcome.

Following are selected conference summaries reported exclusively for The Body by Ian Frank, M.D., Associate Professor of Medicine and Director of Antiretroviral Clinical Research at the Hospital of the University of Pennsylvania, Dan Kuritzkes, M.D., Associate Professor of Medicine and Microbiology at the University of Colorado Health Sciences Center, and Kent Sepkowitz, M.D., Assistant Professor, Department of Medicine, Cornell University Medical College, New York, and Assistant Physician and Associate Chairman Clinical Affairs, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York.

Conference Summaries:

Friday, November 19, 1999

• Pharmacokinetic Analysis of Drugs and Virus in the Cerebrospinal Fluid (CSF) by Intensive Sampling
  Coverage by Daniel Kuritzkes, M.D.
  
  • Abstract 330: Characterization of Lamivudine (3TC, Epivir) Pharmacokinetics in Cerebrospinal Fluid (CSF) and Plasma by Ultra-Intensive Sampling
    
  • Abstract 338: Steady-State Indinavir (Crixivan) Pharmacokinetics in Cerebrospinal Fluid (CSF) and Plasma Determined by Ultra-Intensive CSF-Sampling
    
  • Abstract 339: Kinetics of HIV-1 Entry into Cerebrospinal Fluid (CSF) in Asymptomatic Treatment-Naïve Adults as Determined by Ultra-Intensive CSF-Sampling
    
  • Abstract 340: Detailed Characterization of Stavudine (d4T, Zerit) Pharmacokinetics in Cerebrospinal Fluid (CSF) and Plasma by Ultra-Intensive CSF-Sampling
    

• Abstract 14: A Comparison of d4T, ddI and Indinavir (IDV) with ZDV, 3TC, and IDV as the Initial Treatment of HIV-1: Selection of Thymidine Analog Regimen Therapy (Start II)
  Coverage by Daniel Kuritzkes, M.D.
  
• Abstract 347: HIV Protease Inhibitor-Induced Metabolic Disorders Are Influenced by Genetics and Diet
  Coverage by Daniel Kuritzkes, M.D.
  
• Abstract 348: Hyperlactatemia and Hepatic Abnormalities in Ten HIV-Infected Patients Receiving Nucleoside Analog Combination Regimens
  Coverage by Daniel Kuritzkes, M.D.
  
• Abstract 359: The Effect of Virologic Control on Rates of Disease Progression: Findings from the CHORUS Cohort
  Coverage by Daniel Kuritzkes, M.D.
  
• Abstract 367: Initial T-Cell and Viral Load Responses Among Patients Receiving First-Ever HAART in the HIV Outpatient Study (HOPS)
  Coverage by Daniel Kuritzkes, M.D.
  
• Abstract 375: Are There Gender Differences in HIV Disease Progression?
  Coverage by Daniel Kuritzkes, M.D.
  
• Abstract 442: Virologic Failure and Resistance with Triple Combination Antiretroviral Therapy (START Studies I and II)
  Coverage by Daniel Kuritzkes, M.D.
  

• Genotypic Mutations Associated with Resistance to Antiretrovirals
  Coverage by Ian Frank, M.D.
  
  • Abstract 361: Temporal Relationship Between Development of HIV-1 Resistance Mutations and Viral RNA in Antiretroviral Therapy Experienced Adults on Therapy with Ziagen (Abacavir, ABC) and Combivir (Lamivudine/Zidovudine)
    
  • Abstract 362: Temporal Relationship Between Development of HIV-1 Resistance Mutations and Viral RNA in Antiretroviral Therapy (ART) naïve Adults on Therapy with Ziagen (Abacavir, ABC) and Protease Inhibitors (PI)
    
  • Abstract 442: Virologic Failure and Resistance with Triple Combination Antiretroviral Therapy (START Studies I and II)
    
  • Abstract 365: In-Frame Three Nucleoside Deletions in Reverse Transcriptase are Observed in HIV-1 From Patients During Long Term Antiretroviral Therapy
    

• Antiretroviral Therapy for Treatment Naïve Patients
  Coverage by Ian Frank, M.D.
  
  • Abstract 14: A Comparison of d4T, ddI, and indinavir (IDV) with ZDV, 3TC, and IDV as the Initial Treatment of HIV-1: Selection of Thymidine Analog Regimen Therapy (Start II)
  • Abstract 366: Efavirenz (EFV) + Zidovudine (ZDV) + Lamivudine (3TC) Provides Superior Long-Term HIV-RNA Suppression, Antiretroviral Activity and Tolerability Versus Indinavir (IDV) + ZDV + 3TC: Results of Study 006 at 72 Weeks (Initial Cohort)
  • Abstract 314: Ziagen (Abacavir, ABC) Combined with 3TC & ZDV Provides a Potent & Durable Response Through 48 Weeks in HIV-1 Infected Antiretroviral Therapy - Naïve Subjects (CNA3003)

• Drug Penetration Across the Blood-Brain Barrier
  Coverage by Ian Frank, M.D.
  
  • Abstract 340: Detailed Characterization of Stavudine (d4T, Zerit) Pharmacokinetics in Cerebrospinal Fluid (CSF) and Plasma by Ultra-Intensive CSF Sampling
  • Abstract 338: Steady-State Indinavir Pharmacokinetics in Cerebrospinal Fluid (CSF) and Plasma Determined by Ultra-Intensive CSF Sampling

• Treatment Simplification -- Switching Off Protease Inhibitors
  Coverage by Ian Frank, M.D.
  
  • Abstract 316: Switching Off Protease Inhibitors: An Observational Study of Well Controlled HIV Patients Who Opted to Change to Efavirenz and/or Abacavir Based Regimens After Initial Treatment with Protease Inhibitors
  • Abstract 372: Long Term Efficacy of Protease Inhibitor (PI) Induced HIV-1 Suppression Followed by Switch to Non-PI Maintenance Antiretroviral Therapy

• CD4+ Count Responses -- Connect or Disconnect?
  Coverage by Ian Frank, M.D.
  
  • Abstract 332: Trends in CD4 Count by Response to HAART; A Report from the Women's Interagency HIV Study (WIHS)
  • Abstract 446: Importance of Intial CD4 Cell Response in Patients Achieving Undetectable Levels of HIV RNA

• New Drugs for Old Targets (NRTI, NNRTI, Protease Inhibitor, Nucleotide)
  Coverage by Kent Sepkowitz, M.D.
  • Introduction
  • New Drugs for New Targets

  
  

• Poster Sessions:
  Coverage by Kent Sepkowitz, M.D.
  • Poster 325: In Vitro Hollow Fiber Pharmacodynamic (IVHFP) Studies of Abacavir (ABC) Results of a 30 Day Dose Scheduling Study Evaluating Virus Spread and Emergence of Resistant Virus
  • Poster 327: Pharmacokinetics of Emirivine (Coactinon™, EMV) in HIV-Infected Patients Receiving Stavudine (Zerit®, D4T) and Didanosine (Videx®, DdI)
  • Poster 346: Does the M184V Mutation Effect the Efficacy of HAART -- Sequential Addition of PI's or Abacavir to ZDV/3TC or D4T/3TC
  • Poster 349: Efavirenz Is Well-Tolerated and Highly Efficacious in Combination with the Nucleosides Stavudine (D4T) + Lamivudine (3TC)
  • Poster 351: Antiviral Activity and Tolerability of Emirivine (Coactinon™, EMV) with or without Lead-In Dosing in Combination with Stavudine (Zerit®, D4T) + Didanosine (Videx®, DdI)(MKC-202)
  • Poster 364: Antiviral Activity, Safety, and Tolerability of Emivirine (EMV, Coactinon™) + Stavudine (D4t, Zerit®) + Lamivudine (3TC, Epivir®) in Treatment-Naïve HIV-Infected Volunteers (MKC-301)
  • Poster 437: Update on Immune Function in Pregnancy and HIV Infection